Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort

British Journal of Cancer

Volumn 105, Issue 7, 2011, Pages 890-896

  Zang, R Y ^a   Harter, P ^b   Chi, D S ^c   Sehouli, J ^d   Jiang, R ^a   Trope C G ^e   Ayhan, A ^f   Cormio, G ^g   Xing, Y ^h   Wollschlaeger, K M ⁱ   Braicu, E I ^d   Rabbitt, C A ^c   Oksefjell, H ^e   Tian, W J ^a   Fotopoulou, C ^d   Pfisterer, J ^j   Du Bois, A ^b   Berek, J S ^k  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b KLINIKEN ESSEN MITTE   (Germany)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

^f BASKENT UNIVERSITY   (Turkey)

^g UNIVERSITY OF BARI   (Italy)

^h UNIVERSITY OF TEXAS   (United States)

ⁱ OTTO VON GUERICKE UNIVERSITY   (Germany)

^j Hospital Solingen   (Germany)

^k STANFORD CANCER INSTITUTE   (United States)

more..

Author keywords

ovarian cancer; pooled analysis; recurrence; surgery; survival

Indexed keywords

ARTICLE; ASCITES; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; COHORT ANALYSIS; CYTOREDUCTIVE SURGERY; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; CYSTADENOCARCINOMA, SEROUS; ENDOMETRIAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERNATIONAL AGENCIES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; OVARIECTOMY; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80053242297     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.328     Document Type: Article

References (29)

1. Alberts DS, Liu PY, Wilczynski SP, Clouser MC, Lopez AM, Michelin DP, Lanzotti VJ, Markman M (2008) Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200). Gynecol Oncol 108: 90-94 (Pubitemid 350299426)
2. Berek JS, Hacker NF, Lagasse LD, Nieberg RK, Elashoff RM (1983) Survival of patients following secondary cytoreductive surgery in ovarian cancer. Obstet Gynecol 61: 189-193 (Pubitemid 13110698)
3. Bristow RE, Puri I, Chi DS (2009) Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol Oncol 112: 265-274
4. Chi DS, McCaughty K, Diaz JP, Chi DS, McCaughty K, Diaz JP, Huh J, Schwabenbauer S, Hummer AJ, Venkatraman ES, Aghajanian C, Sonoda Y, Abu-Rustum NR, Barakat RR (2006) Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer 106: 1933-1939 (Pubitemid 43673208)
5. Chmura Kraemer H (1992) Evaluating Medical Tests: Objective and Quantitative Guidelines. SAGE: Newbury Park, CA
6. du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J (2009) Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsge-meinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer 115: 1234-1244
7. Eisenkop SM, Friedman RL, Spirtos NM (2000) The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer 88: 144-153 (Pubitemid 30027690)
8. Graham JW (2009) Missing data analysis: making it work in the realworld. Ann Rev Psychol 60: 549-576
9. Harter P, Bois AD, Hahmann M, Harter P, du Bois A, Hahmann M, Hasenburg A, Burges A, Loibl S, Gropp M, Huober J, Fink D, Schröder W, Muenstedt K, Schmalfeldt B, Emons G, Pfisterer J, Wollschlaeger K, Meerpohl HG, Breitbach GP, Tanner B, Sehouli J (2006) Surgery in recurrent ovarian cancer: the arbeitsgemeinschaft gynaekologische onkologie (AGO) DESKTOP OVAR Trial. Ann Surg Onco l 13: 1702-1710 (Pubitemid 44951480)
10. He Y, Zaslavsky AM, Harrington DP, Catalano P, Landrum MB (2010) Multiple imputationin a large-scale complex survey: a practical guide. Stat Methods Med Res 19: 653-670
11. Hennessy BT, Coleman RL, Markman M (2009) Ovarian cancer. Lancet 374: 1371-1382
12. Jänicke F, Hölscher M, Kuhn W, von Hugo R, Pache L, Siewert JR, Graeff H (1992) Radical surgical procedure improves survival time in patients with recurrent ovarian cancer. Cancer 70: 2129-2136
13. Klebanoff MA, Cole SR (2008) Use of multiple imputation in theepide-miologic literature. Am J Epidemiol 168: 355-357
14. Morris M, Gershenson DM, Wharton JT, Copeland LJ, Edwards CL, Stringer CA (1989) Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Gynecol Oncol 34: 334-338 (Pubitemid 19218573)
15. Oksefjell H, Sandstad B, Tropé C (2009) The role of secondary cytoreduction in the management of the first relapse in epithelial ovarian cancer. Ann Oncol 20: 286-293
16. Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, Wheeler S, Swart AM, Qian W, Torri V, Floriani I, Jayson G, Lamont A, Tropé C (2003) Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361: 2099-2106
17. Pfisterer J, Plante M, Vergote I, du Bois A, Hirte H, Lacave AJ, Wagner U, Stähle A, Stuart G, Kimmig R, Olbricht S, Le T, Emerich J, Kuhn W, Bentley J, Jackisch C, Lück HJ, Rochon J, Zimmermann AH, Eisenhauer E (2006) Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 24: 4699-4707 (Pubitemid 46630933)
18. Power P, Stuart G, Oza A, Provencher D, Bentley JR, Miller Jr WH, Pouliot JF (2009) Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: a phase II study. Gynecol Oncol 114: 410-414
19. Rubin DB (1987) Multiple Imputation for Nonresponse in Surveys. John Wiley and Sons: New York, NY
20. Rustin GJ, van der Burg ME, Griffin CL, Rustin GJ, van der Burg ME, Griffin CL, Guthrie D, Lamont A, Jayson GC, Kristensen G, Mediola C, Coens C, Qian W, Parmar MK, Swart AM, MRC OV05, EORTC 55955 investigators (2010) Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet 376: 1155-1163
21. Salani R, Santillan A, Zahurak ML, Giuntoli II RL, Gardner GJ, Armstrong DK, Bristow RE (2007) Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome. Cancer 109: 685-691 (Pubitemid 46233229)
22. Schisterman EF, Perkins NJ, Aiyi L, Bondell H (2005) Optimal cut-point and its corresponding Youden index to discriminate individuals using pooled blood samples. Epidemiology 16: 73-81 (Pubitemid 40239280)
23. Segna RA, Dottino PR, Mandeli JP, Konsker K, Cohen CJ (1993) Secondary cytoreduction for ovarian cancer following cisplatin therapy. J Clin Oncol 11: 434-439 (Pubitemid 23071038)
24. Sehouli J, Stengel D, Oskay-Oezcelik G, Zeimet AG, Sommer H, Klare P, Stauch M, Paulenz A, Camara O, Keil E, Lichtenegger W (2008) Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the NorthEastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J Clin Oncol 26: 3176-3182
25. Tian WJ, Chi DS, Sehouli J, Tropé CG, Jiang R, Ayhan A, Cormio G, Xing Y, Breitbach GP, Braicu EI, Rabbitt CA, Oksefjell H, Fotopoulou C, Meerpohl HG, du Bois A, Berek JS, Zang RY, Harter P (2011) A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection. Ann Surg Oncol 2011; e-pub ahead of print 6 July 2011; doi:10.1245/s10434-011-1873-2
26. Tian WJ, Jiang R, Cheng X, Tang J, Xing Y, Zang RY (2010) Surgery in recurrent epithelial ovarian cancer: benefits on survival for patients with residual disease of 0.1-1 cm after secondary cytoreduction. J Surg Oncol 101: 244-250
27. Vaccarello L, Rubin SC, Vlamis V, Wong G, Jones WB, Lewis JL, Hoskins WJ (1995) Cytoreductive surgery in ovarian carcinoma patients with a documented previously complete surgical response. Gynecol Oncol 57: 61-65
28. Zang RY, Li ZT, Tang J, Cheng X, Cai SM, Zhang ZY, Teng NN (2004) Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits? Cancer 100: 1152-1161 (Pubitemid 38325942)
29. Zang RY, Zhang ZY, Li ZT, Chen J, Tang MQ, Liu Q, Cai SM (2000) Effect of cytoreductive surgery on survival of patients with recurrent epithelial ovarian cancer. J Surg Oncol 75: 24-30